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Abstract
Infantile GM1 gangliosidosis is caused by the absence or reduction of lysosomal beta-galactosidase activity. Studies
conducted in Brazil have indicated that it is one of the most frequent lysosomal storage disorders in the southern part
of the country. To assess the incidence of this disorder, 390 blood donors were tested for the presence of two com-
mon mutations (1622-1627insG and R59H) in the GLB1 gene. Another group, consisting of 26 GM1 patients, and the
blood donors were tested for the presence of two polymorphisms (R521C and S532G), in an attempt to elucidate
whether there is a founder effect. The frequencies of the R59H and 1622-1627insG mutations among the GM1 pa-
tients studied were 19.2% and 38.5%, respectively. The frequency of polymorphism S532G was 16.7%, whereas
R521C was not found in the patients. The overall frequency of either R59H or 1622-1627insG was 57.7% of the dis-
ease-causing alleles. This epidemiological study suggested a carrier frequency of 1:58. Seven different haplotypes
were found. The 1622-1627insG mutation was not found to be linked to any polymorphism, whereas linkage disequi-
librium was found for haplotype 2 (R59H, S532G) (p < 0.001). These data confirm the high incidence of GM1
gangliosidosis and the high frequency of two common mutations in southern Brazil.
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GM1 gangliosidosis and mucopolisaccharidosis IV-
B (Morquio B) are lysosomal storage disorders caused by a
-galactosidase(GLB1;EC3.2.1.23)deficiency.Thisdefi-
ciency occurs due to mutations in the GLB1 gene, but the
differences that lead either to GM1 gangliosidosis or to
Morquio B are not known so far. GLB1 is located on chro-
mosome 3 at 3p21.33 (Takano and Yamanouchi, 1993) and
is composed of 62.5 kb divided into 16 exons (Morreau et
al., 1989). Hypotheses have been raised proposing that
more than 100 different mutations could be responsible for
the Morquio or GM1 gangliosidosis phenotypes (Callahan,
1999; Brunetti-Pierri and Scaglia, 2008). However, pa-
tients with intermediate phenotypes have also been de-
scribed (Giugliani et al., 1987; Mayer et al., 2009).
The incidence of type 1 GM1 gangliosidosis is con-
sidered to be between 1:100,000 and 1:200,000 live births
(Sinigerskaetal.,2006).However,higherfrequencieshave
beendescribedforspecificregions,suchasMalta(1:3,700)
(Lenickeretal.,1997).TheincidenceinBrazilhasbeenes-
timated at 1:17,000 live births, and the carrier frequency
was found to be 1:67 (Severini et al., 1999). Mutation anal-
ysis performed in 19 Brazilian patients detected the pres-
ence of mutations 1622-1627insG (Silva et al., 1999)
and/or R59H (Morrone et al., 1997) in about 60% of the al-
leles. These results stand out when compared to mutation
frequencies found by other groups in different parts of the
world.
Here, we report a screen to detect and confirm the in-
cidenceoftype1GM1gangliosidosisinsouthernBrazilby
analyzing 390 anonymous blood donor samples for the
presence of the two common mutations. In addition, these
controlsamplesandagroupof26GM1patientsweretested
for the presence of two polymorphisms located within the
GLB1 gene, in an attempt to elucidate whether there is a
founder effect, which could explain the high frequency of
this disorder in the studied region.
Mutationanalysiswasperformedonsamplesfrom26
unrelated patients with GM1 gangliosidosis and their rela-
tives(wheneverpossible)todeterminetheligationphaseof
the alleles.
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Short CommunicationPatients were diagnosed at the Laboratory of Inborn
Errors of Metabolism of the Hospital de Clínicas de Porto
Alegre (LREIM/HCPA), Brazil. The diagnosis was con-
firmed by low levels of -galactosidase enzyme activity in
leukocytes. Anonymous control samples were collected
from blood donors of the HCPA Blood Bank, for a total of
390 samples.
Genomic DNA was extracted from peripheral blood
leukocytes, using the salting-out procedure (Miller et al.,
1988). Molecular analysis was performed using PCR for
exons 2 and 15, in order to detect the R59H, 1622-
1627insG, R521C and S532G mutations. Primers and con-
ditions were as described by Silva et al. (1999). The PCR
fragments of exon 2 were digested with NlaIII (New Eng-
land Biolabs) and visualized on a 3% agarose gel, to assess
for the presence of the R59H mutation. Gels for SSCP (sin-
gle-strand conformation polymorphism) analysis of exon
15contained25%MDE(MutationDetectionEnhancement
– FMC) and 5% glycerol, and were run for 14-15 h at
250V/4W at room temperature. The gels were silver-
stainedasdescribedbyOritaetal.(1989).Alterationswere
identified by comparison with known sequenced samples.
Nucleotide sequences were aligned using the Alignment
Explorer/ClustalWMolecularEvolutionaryGeneticsAnal-
ysis (MEGA) software version 4.0 (Tamura et al., 2007).
Linkage disequilibrium was calculated using the DNA Se-
quence Polymorphism 5 (DNASP) program (Rozas and
Rozas, 2000) and the haplotype construction.
Weinvestigated26patientswithGM1gangliosidosis
formutationsR59Hand1622-1627andforpolymorphisms
R521C and S532G. Twenty-two patients had one or both
mutations. The frequencies of R59H and 1622-1627insG
were 19.2% and 38.5%, respectively (Table 1). The fre-
quency of the S532G polymorphism was 15.4%, while that
of the R521C polymorphism was 0 (zero); the latter poly-
morphismwashoweverpresentinoneoftheparentsoffour
patients. Four patients presented none of the aforemen-
tioned mutations.
The frequencies of these two disease-causing muta-
tions and of the two polymorphisms in 390 control subjects
are also shown in Table 1. The R59H mutation was in
heterozygosis in one subject, and the 1622-1627insG was
inheterozygosisinanotherthree.Theestimatedoverallfre-
quency of these two mutations is 0.5% in the normal popu-
lation of Porto Alegre. The higher frequency of polymor-
phism S532G in patients (0.154) than in controls (0.074)
wasmarginallysignificant(p=0.046,Fisher’sExactTest),
whereas R521C showed no difference between the two
groups.
Because R59H and 1622-1627insG correspond to
57.7%ofthedisease-causingalleles,itwaspossibletoesti-
mate the frequency of mutant alleles in the population of
Porto Alegre at 0.0007509 and the carrier proportion at
1:58. These figures would lead to a disease incidence of
1:13,317 live births.
Polymorphisms R521C and S532G were used in ha-
plotypeanalysistoidentifyafoundereffectintheBrazilian
population.Sevendifferenthaplotypeswerefound.Table2
showsthehaplotypefrequenciesinpatientsandincontrols.
In about 10% of the patients and 2% of the controls it was
not possible to determine the haplotypes.
In the patient group, haplotype 2 was the most fre-
quent (36.5%), but close to haplotype 1 (34.6%). Haplo-
types3and7werefoundonlyinthecontrolgroup,inwhich
haplotype 1 was the most frequent (89.1%). The 1622-
1627insG mutation was not found to be in linkage disequi-
librium with any polymorphism, whereas R59H was found
tobeinlinkagedisequilibriumwithS532G(haplotype5)in
the patient group (p < 0.001).
Severini et al. (1999) reviewed 63 GM1 type I cases
diagnosed at the LREIM/HCPA and found that 68% were
46 Baiotto et al.
Table 1 - Allele frequencies in patients and controls.
Alleles Patients Controls
R59H 10/52 = 0.192 1/780 = 0.001
1622-1627insG 20/52 = 0.385 3/780 = 0.004
S532G 8/52 = 0.154 58/780 = 0.074
R521C 0/52 = 0.0 21/780 = 0.027
Table 2 - Haplotype frequencies (as to the presence of R59H and 1622-1627insG mutations and R521C and S532G polymorphisms) in patients and con-
trols.
Haplotype R59H;1622-1627insG; R521C;S532G* Patients (n = 52) Controls (n = 780)
1 1-1-1-1 0.346 0.891
2 1-2-1-1 0.365 0.003
3 1-2-1-2 0.0 0.001
4 2-1-1-1 0.058 0,001
5 2-1-1-2 0.097 0.0
6 1-1-1-2 0.019 0.068
7 1-1-2-1 0.0 0.019
8 ND 0.115 0.016
* 1 = wild-type allele; 2 = mutant allele; ND = not determined.from the State of Rio Grande do Sul. The epidemiological
study suggested a carrier frequency of 1:67. This observa-
tion was confirmed by the molecular analysis of the
390 control subjects of the present work. The presence of
four heterozygous individuals led to the determination of a
carrier frequency of 1:58 in Porto Alegre. This number is
similartothephenylketonuriacarrierfrequencyinthesame
area(1:56)(SantanadaSilvaetal.,2003)andsimilartothat
of Gaucher and Tay-Sachs disease carriers among Ashke-
nazi Jews (Risch et al., 2003).
Usingthesefigures,wewereabletoestimatetheinci-
denceofGM1type1inPortoAlegreat1:13,317livebirths,
slightly higher than that of 1:17,000 live births reported by
Severini et al. (1999). These frequencies are extremely
high when compared to those found in other studies, re-
ported to be 1:100,000-1:200,000 (Beattie and Harvey,
1992; Sinigerska et al, 2006) and 1:320,000 (Meikle et al.,
1999). The small proportion of consanguineous couples in
our sample (a single case out of 26) is also consistent with
thehighincidenceofthisdisorderinBrazil,especiallycon-
sidering that 27% of the patients were found to be homozy-
gous for one of the two analyzed mutations.
The two mutations (R59H and 1622-1627insG) were
detected in 57.7% of the alleles. This number is quite high
for a heterogeneous genetic disorder like GM1 ganglio-
sidosis, for which about 100 mutations were described
(Brunetti-Pierri and Scaglia, 2008). The R59H mutation
was first described by Morrone et al. (1997) in an Italian
patient. Silva et al. (1999) found this mutation in 23.8% of
theallelesof20Brazilianpatients.Thesepatientspresented
cardiac involvement similar to that described by Morrone
et al. (2000). Santamaria et al. (2006) and Sinigerska et al.
(2006)suggestedthattheR59HmutationisofGypsyorigin
and that the presence of this mutation in South America is a
reflection of their diaspora.
The 1622-1627insG mutation has only been reported
inBrazilianpatientssofar,exceptforonepatientfromUru-
guay described by Santamaria et al. (2007a). Silva et al.
(1999)foundafrequencyof42.8%forthismutation.Taken
together,thesetwomutationsshowedafrequencyof62.5%
in the patients studied by Silva et al. (1999), which is simi-
lar to the one found in the present work (57.7%).
Polymorphism S532G was significantly more fre-
quent in patients than in controls. It is not clear if this alter-
ation has an effect on protein activity, because expression
data showed contradictory results, with values ranging
from 41% (Hilson et al., 1995) to 86% (Zhang et al., 2000)
of normal enzyme activity.
TheR521Cpolymorphismwasfoundonlyincontrols
andinfourparentsofpatients,butnotinanyofourpatients.
This polymorphism was first described by Silva et al.
(1999) and was present in 10% of patients’ alleles. How-
ever, in that sample, this polymorphism was found in pa-
tients bearing other mutations than the ones studied in this
work.Caciottietal.(2005)describedapatientwhowasho-
mozygous for R521C and assumed that it was likely to be
the disease-causing mutation. In the work of Santamaria et
al. (2007b), the R521C polymorphism resulted in 33.2%
enzyme activity. This observation could explain the appar-
entparadoxof4%ofthegeneralpopulationofPortoAlegre
carrying the R521C mutation, since it could have a low
penetrance rate (Santamaria et al., 2007b).
The lower frequency of haplotypes 6 (S532G only)
and 4 (R59H only) in relation to haplotype 5 (R59H and
S532G) suggests that each of these DNA changes took
placeindependentlyandthatrecombinationeventswerere-
sponsible for their grouping in haplotype 5. Moreover, the
statistical analysis indicated the occurrence of at least one
recombination event.
Itwasnotpossibletopreciselydefinetheexistenceof
a founder effect, despite the high frequency of 1622-
167insG among patients, because this mutation was not
linked to any of the polymorphisms studied. As this muta-
tion is an insertion of one G into a string of six Gs, multiple
origins cannot be ruled out. However, if this were the case,
this mutation would be expected to have also been found in
other populations. The fact that this mutation was never re-
ported in any other region is strongly suggestive of a
foundereffectinthesouthernpartofBrazilandinUruguay.
Supporting this hypothesis, there is the high proportion of
homozygous patients with a low consanguinity rate found
in this work and by Silva et al. (1999) in the same popula-
tion.
The data obtained in this study confirm the high inci-
dence of Type 1 GM1 gangliosidosis and the high fre-
quency of two common mutations (R59H and 1622-
1727insG)insouthernBrazil.Itwas,however,notpossible
toprovethatthehighfrequencyofthelattermutationisdue
to a founder effect.
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